Dicerna Pharmaceuticals reported $-29107000 in Operating Profit for its first fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Profit Change
Agenus AGEN:US $ -41.37M 19.66M
Alnylam Pharmaceuticals ALNY:US $ -186.25M 7.97M
Amgen AMGN:US $ 2129M 121M
Arrowhead Research ARWR:US $ -28232000 4.18M
Biogen BIIB:US $ 973.9M 1304.5M
Bluebird Bio BLUE:US $ -231.21M 27.23M
Dicerna Pharmaceuticals DRNA:US $ -29.11M 2.54M
Exelixis EXEL:US $ -4.61M 28.9M
Gilead Sciences GILD:US $ 2890M 239M
GlaxoSmithKline GSK:LN 1.69B 632M
Immunogen IMGN:US $ -28.92M 65.44M
Intercept Pharmaceuticals ICPT:US $ -29.35M 11.26M
Intrexon XON:US $ -17.69M 21.23M
IONIS PHARMACEUT IONS:US $ -91.97M 69.31M
Karyopharm Therapeutics KPTI:US $ -52373000 15.31M
Lexicon Pharmaceuticals LXRX:US -20839000 14.64M
Macrogenics MGNX:US $ -51293000 49.12M
Merk MRK:US $ 3042M 5291M
Mirati Therapeutics MRTX:US $ -132.42M 26.09M
Pfizer PFE:US $ 5517M 5340M
Regeneron Pharmaceuticals REGN:US $ 1112.7M 54.3M
Regulus Therapeutics RGLS:US $ -5.8M 4.77M
Ultragenyx Pharmaceutical RARE:US $ -106.57M 10.49M